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Abstract Bone marrow examination (BME) represents an
essential tool for diagnosis and monitoring of haematolog-
ical disorders. It remains associated with morbidity and
discomfort; repeat examinations are frequent. We made a
single-centre prospective survey on 700 BME between July
2007 and July 2008 with a structured anonymized
questionnaire for patients undergoing and physicians
performing BME, which includes at our institution always
aspiration and trephine. All procedures were performed
according to institutionalised standard operating proce-
dures; 412 patients' (58.9%) and 554 physicians' (79.1%)
questionnaires were returned. Pain was the only procedure-
related complication; no pain was reported in 149 (36.7%),
bearable pain in 242 (59.6%) and unbearable pain in 15
(3.7%) cases. Premedication associated complications were
reported by 110 (32.7%) of the 336 (65.4%) patients with
premedication before BME. None of these were > WHO
grade 2; most frequently reported were tiredness (76
patients; 22.6%), dizziness (19 patients; 5.7%) and nausea
(15 patients; 4.5%). Only two factors were significantly
associated with unbearable pain: “pain during prior BME”
(seven of 94 with versus one of 198 without previous pain;
p<0.01) and “information before BME” (four of 11 without
versus 12 of 372 with adequate information before BME;
p<0.01). Inadequate information at any time showed a trend
towards an association with unbearable pain (p=0.08). No
other factor was associated with unbearable pain. Good and
adequate information appears to be the best way to reduce
pain, even for a future BME.
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Introduction
Examination of the bone marrow is a central element for the
diagnosis of haematological disorders and the management
of these patients. Bone marrow aspirations and biopsies
provide material for essential cytological, histological,
cytogenetic, immunphenotyping or molecular analyses
which cannot be obtained by other methods than bone
marrow aspiration and trephine. In experienced hands, bone
marrow examination (BME) is associated with low mor-
bidity and mortality and is considered as an established
method [1–4]. Still, some side effects are known and well
described. The best investigated and most frequent compli-
cation is pain [5, 6]. It has been reported as moderate to
severe in about one third of the patients in a recent study. In
the same study, age of the patient and duration of the
procedure were reported as key factors associated with
more severe pain [6]. For many investigators, pain is
considered as inacceptable for patients and at least some
form of anaesthesia or premedication is suggested in order
to reduce pain during BME. Multiple studies have shown
good effects and low morbidity with the commonly used
opioids and benzodiazepines [6–15].
Still for most patients, BME is considered as an
unpleasant painful procedure with possible complications.
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Many are afraid of BME, in most cases without any
knowledge about the exact details of the diagnostic
procedure. Studies so far have primarily focussed on
incidence and severity of complications or side effects and
on methods to prevent them. Little is known, in contrast,
about factors associated with the subjective and objective
experience of pain. This study was initiated in order to
close this gap and to hopefully identify factors associated
with pain experienced during BME through a prospective
survey of patients and physicians. The primary endpoint
was subjective unbearable pain.
Patients and methods
Study design
This was a prospective single centre survey-study at the
University Hospital Basel. All patients undergoing a BME
in the haematology in- or outpatient unit by a staff member
of the haematology team between 1st of July 2007 and the
31st of July 2008 were included. All were given a
questionnaire and asked, to return it the next day in a self
addressed envelope. A separate questionnaire was given to
the physician performing the BME with a self addressed
envelope. Only the primary investigator (C.D.) was able to
match the patients' and physicians' questionnaire by a
numbering code.
The questionnaires for patients did include ten questions
relating to their subjective experience of the procedure, on
the information and assistance before, during and after the
procedure, the experienced side effects and complications.
The questionnaire for physicians did include 17 questions
relating to objective observation of the procedure including
disease, coagulation status, premedication, local anaesthe-
sia, the numbers of necessary biopsies and aspirations, the
observed side effects and complications and, the qualifica-
tion of the staff member (junior, senior staff).
A total of 700 BME were included and 700 question-
naires distributed. Of these, 554 (79.1% return rate)
questionnaires from physicians and 412 (58.9% return rate)
questionnaires from patients were sent back. From 370
BME, corresponding questionnaires from both, patients and
physicians were obtained.
The study was approved by the ethics committee of the
cantons Basel-Stadt and Basel-Landschaft.
Patient population
The 527 returned questionnaires were answered by 128
(55.4%) male patients with a median age of 57.1 years,
ranging from 20 to 95 years. Main disease indications for
the BME were acute myeloid leukaemia with 96 (24.2%)
patients, multiple myeloma with 60 (15.2%) patients and
chronic myeloid leukaemia with 44 (11.1%) patients,
reflecting primarily the population of a stem cell transplant
unit. If a patient was undergoing a repeated BME in the
study time, he was asked to fill in the questionnaire again.
Thirty-eight patients were undergoing multiple BMEs in the
study time. In 116 (22.0%) examinations, the investigated
BME was the first one for this patient.
Bone marrow examination
All BME were performed according to a standard operating
procedure (SOP) for bone marrow examinations of the
University Hospital Basel. All junior staff members are
trained for the procedure by a senior staff member. In every
BME a physician and a specially trained nurse is present.
The patient lies on a examination bed on his abdomen and
the samples are taken standardly of the posterior crista
iliaca. The aspirations are done with a 20-ml syringe with
2 ml Heparin and two 10-ml syringes each with 3 ml
ethylenediaminetetraacetic acid (EDTA). While one EDTA
syringe is filled with high pressure, the other two syringes
are filled slowly with bone marrow. All in all 13 ml bone
marrow is taken with the EDTA syringes and 15 ml bone
marrow with the Heparin syringe. After the aspiration, the
biopsy is taken and given in a container with SUSA.
Afterwards the wound is coered sterile and compressed for
half an hour in minimum. Immediately after the BME the
biopsy and the aspiration are brought in the haematology
labour for the asked investigations. During the study period,
the haematology labour at the University Hospital of Basel
performed 1,252 bone marrow samples. 376 (30.0%) were
from another hospital. Liberal use of lidocain® 2% for local
anaesthesia is part of the SOP. In our study, the median
dose was 9.5 ml (range, 2–20 ml). Premedication with
opioids or benzodiazepines were given liberally on patient’s
demand. Standard according to the SOP is a premedication
with 25–50 mg Pethidinhydrochlorid (Pethidin®) i.v. and
Midazolam (Dormicum®) 2-10 mg i.v. The side effects are
discussed with every patient. In most cases, a compound of
Midazolam i.v. (median, 3.36 mg; range, 1.0–12.0 mg) and
Pethidinhydrochlorid i.v. (median, 30.69 mg; range, 10.0–
75.0 mg) is used.
BME at the University Hospital of Basel includes always
aspiration and trephine both are obtained during the same
session with a HS Hospital Service S.P.A, Trap System
11Gx100MM bone marrow examination set.
Statistical analysis
The statistical analysis comparisons were made by the
Omnibus-test and the Hosmer–Lemeshow test using the
statistic software SPSS Ver. 12.
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Because of low frequencies of some factors, exact
significances (Fisher–Yates test in 2×2 tables or Freeman
and Halton in 2×k tables) were calculated [16]. P values
<0.05 were considered significant.
Results
Complications
The numbers of reported complications are summarised in
Table 1. There were no bleeding or infectious complications
observed or reported during this 13-month period of 554
BME. The only complication reported and directly related to
the BME was pain; 406 patients mentioned pain in their
response. Of these, no pain was reported by about one third;
near 60% of the patients complained about mild to moderate
pain, 15 patients (3.7%) about unbearable pain (Fig. 1).
More complications were reported as a consequence of
premedication. A total of 336 (65.4%) patients had been
given premedication before BME. One hundred ten of them
(32.7%) reported at least one side effect; none was severe
enough to require prolonged hospitalisation. The most
frequent complications after the premedication were fatigue
in 76 (22.6%) cases, dizziness in 19 (5.7%) cases and
nausea in 15 (4.5%) cases. In contrast, 226 (67.3%) were
satisfied and had no complications by their premedication.
Factors associated with pain
Questionnaires from physicians and patients did cover
different topics; therefore, some factors associated with
pain could only be looked at when both forms were
returned (n=370). This explains the slightly divergent
numbers for certain examinations.
For 82 patients (23.2%), the reported BME was their
first examination; of these, 76 (92.7%) reported no to
moderate pain. This number was slightly lower than those
reported from patients with prior BME (265 patients;
97.4%; p=0.08).
Pain during a prior BME had an impact on pain during a
subsequent examination. From 199 patients who had no
pain in prior examinations, only one (0.5%) did report
unbearable pain. In contrast, seven of 94 patients with pain
during a prior BME reported unbearable pain during their
subsequent BME (p<0.01).
Numbers of attempts to obtain sufficient material from
the BME was not significantly associated with pain. This
related to attempts for biopsy as well as for attempts to
obtain adequate aspiration material. In 487 (90.9%)
examinations, the biopsy was successful with one attempt;
maximum was five attempts. In 475 (88.8%) examinations,
the aspiration was successful with one attempt; maximum
were six aspiration attempts. The proportion of patients
with unbearable pain was 3.3% for the 320 patients with
one attempt for a biopsy compared to the higher proportion
of 5.9% for the 32 patients with repetitive BME attempts
(p=0.62). This was comparable with the aspiration
attempts, with unbearable pain for 3.1% of the 313 patients
with one attempt for a biopsy compared to 7.1% of the 39
patients with repetitive aspiration attempts (p=0.18).
Age had no impact on severe pain. Four percent of the 75
patients below age 60 years complained about unbearable
pain, 5.8% of the 103 patients older than 60 years (p=0.74).
Three hundred ten (89.9%) bone marrow examinations
were done by a physician with more than ten BMEs
experience; 298 (96.1%) patients had bearable pain like 34
(97.1%) which were examined by a physician with less than
ten bone marrow examinations experience. The experience
of the physician had no impact on pain (p=1.00).
Body weight had no impact on severe pain; 3.9% of the
279 patients with body weight within normal range
complained about unbearable pain, compared with 2.4%
of the 83 adipose (p=0.74).
Number of patients Percent
Procedure-related complications Pain No 149 36.7
Bearable 242 59.6
Unbearable 15 3.7
Serious bleeding Yes 0 0
No 554 100.0
Infection Yes 0 0
No 554 100.0
Premedication-related complications No 226 67.3
Dizziness 19 5.7
Nausea 15 4.5
Fatigue 76 22.6
Table 1 Complications in 554
bone marrow examinations
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Quality of information was in general good. In their
response, 393 (96.8%) reported to be satisfied with the
information obtained, prior, during and after the BME. Of
these, 13 patients complained about unbearable pain (3.3%);
in contrast, two of 11 patients with unsatisfactory information
complained about unbearable pain (18%; p=0.08).
In 405 examinations, the patients were satisfied with the
assistance during the procedure and 14 (3.5%) patients
complained about unbearable pain. Of the five patients who
were not satisfied with assistance, only one suffered
unbearable pain (p=0.17).
Two hundred seventy-eight (61.0%) patients had a
prior premedication, primarily with Midazolam and
Pethidinhydrochlorid in an adequate dose. Premedica-
tion did reduce pain but not prevent unbearable pain.
The proportion of patients with unbearable pain was
similar in patients with or without premedication (3.0%
versus 2.8%; p=0.56). These results are summarised in
Table 2.
Discussion
This prospective study, performed at the University
Hospital of Basel, a tertiary centre for severe bone marrow
disorders, identified pain in previous bone marrow exami-
nations and inadequate information during the procedure as
the main and significant factors associated with unbearable
pain during bone marrow examination. The study con-
firmed the safety of the procedure with no complications
associated with BME except pain, if indeed BME is
performed in experienced hands with adequate training
and according to standard operating procedures. Prolonged
bleeding, infectious complications or prolonged pain,
reported complications in the context of BME by others
were not observed [1–4]. The only complications besides
bearable pain (n=242) 
59.6%
no pain (n=149)
36.7%
unbearable pain (n=15) 
3.7%
Fig. 1 Proportions of patients with pain during bone marrow
examination
Table 2 Factors associated with unbearable pain during BME
Factors examined Bearable pain Unbearable pain P value
Prior bone marrow examination Yes 265 7 0.085
No 76 6
Pain during prior examination Yes 94 7 0.002a
No 198 1
Number of attempts for biopsy 1 320 11 0,620
>1 32 2
Numbers of attempts for aspiration 1 313 10 0.179
>1 39 3
Age of patient 1990–1950 72 3 0.736
1950–1910 97 6
Physicians experience 1–10 34 1 1.000
>10 298 12
Adipositas Yes 81 2 0.740
No 268 11
Quality of information overallb Satisfactory 380 13 0.079
Unsatisfactory 11 2
Quality of information before examinationb Satisfactory 372 11 0.002a
Unsatisfactory 12 4
Quality of assistancec Satisfactory 391 14 0.171
Unsatisfactory 4 1
Premedication Yes 268 10 0.560
No 173 5
Numbers refer to patients reporting pain in association with the specific factors. Hence, numbers do not add up to the same numbers for all factors
alike
a Identifies significant factor
b “Unsatisfactory” refers to patients, who were unhappy with the information either before, during or after the examination
c “Unsatisfactory” refers to patients, who were unhappy with the assistance either before, during or after the examination.
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pain, fatigue, dizziness and nausea, were reported as
secondary to the premedication.
The incidence of 3.7% severe pain, reported on a
subjective scale by the patients as unbearable, was low
compared with reports from the literature where, in a recent
survey from 2003, 15.9% of the patients complained about
severe pain [6]. This difference could be due to the study
design, the standardised approach by using a SOP or, by
different cut-offs for unbearable pain. Still, 3.7% of patients
with unbearable pain could be considered as too high and
as an argument for standardised routine application of
premedication. In contrast to the literature [6–15], we did
not find a significant correlation between the use of
premedication and serious pain; a similar proportion of
patients with and without premedication complained about
unbearable pain (p=0.56). These results differ with the
observation of Vanhelleputte et al. who showed, that
patients in the Tramadol group had significantly less pain
during bone marrow aspiration then patients given placebo
(VAS 16.5 versus VAS 28.8; p=0,003) [6]. An explanation
could be that Vanhelleputte did look at the mean VAS
reports only, not at the proportion of patients with
“unbearable” pain. Even though most reports of randomised
controlled trials report a reduction of pain with premed-
ication, our results are compatible with other observations.
Wolanskyj et al. did not see a significant pain reduction by
Lorazepam and Morphin in their study in 2000 (p=0.21)
[7]. Giannoutsos et al. showed in a retrospective study in
2004, that 76 from 112 patients did choose not to have a
premedication before BME and that 74 of this 76 were
happy with their decision [8]. The reported side effects of
premedication and its morbidity and mortality in general are
very low. Reduction of pain has to be balanced by the
patient and the treating physician with the potential side
effects, such as prolonged nausea, fatigue and dizziness,
which might be more important in the outpatient clinic,
where patients might need to drive back home or have to
stay longer.
The key findings of our study were the factors identified
with an association to severe pain. Neither age, sex, body
mass index, premedication, number of attempts, nor
experience of the examining physician or quality of
assistance during BME were found to be significantly
associated. These observations are in part in line with
previous reports, except the premedication, experience of
the physician and even though age was found important in
one study, while it seems to play a minor role in another
study [5, 6]. The main findings were pain during a prior
BME and inadequate information. The factor “good
information” showed a trend when analysed as overall
factor. It was found significant when the information before
BME was considered separately with significantly more
serious pain in patients who were unhappy with their
information prior the BME (p<0.01). These findings can
easily be explained. Well-informed patients can arrange a
mental strategy and have less often serious pain. Patients
with serious pain generally had a worse image about the
examination and concerning the physician. Patients with
severe pain might no longer remember the quality of the
information. Probably, serious pain might reflect a marker
for a physician, who is also not that careful in giving for
example the local anaesthesia. This might specifically relate
to the first examination in order not to traumatise the patient
for future examinations. This fits with the report from Park
et al. who showed in 2008 that patients, who had
Lorazepam before the examination, were significant more
often ready to accept a future BME [9].
What are the consequences of this report? The data
clearly show the big influence of good information by the
physician to reduce pain during invasive examination. It is
probable that these results apply for all sorts of invasive
examinations, not just bone marrow examinations. This fact
is often underestimated in clinical daily routine but could be
an effective simple way to reduce pain during examina-
tions. The data as well suggest, in line with the literature,
that advantages and disadvantages of premedication should
be discussed with the patients and that the approach should
integrate patients' preferences.
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